特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
市場調査レポート
商品コード
925493

バイオ医薬品受託製造の世界市場:成長、動向、予測(2020年~2025年)

Biopharmaceuticals Contract Manufacturing Market - Growth, Trends, and Forecast (2020 - 2025)

出版日: | 発行: Mordor Intelligence LLP | ページ情報: 英文 120 Pages | 納期: 2-3営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=105.81円
バイオ医薬品受託製造の世界市場:成長、動向、予測(2020年~2025年)
出版日: 2020年02月01日
発行: Mordor Intelligence LLP
ページ情報: 英文 120 Pages
納期: 2-3営業日
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 目次
概要

バイオ医薬品受託製造市場は、予測期間中に7.5%のCAGRで成長すると予想されています。受託製造組織(CMO)は、バイオ医薬品業界の企業に契約ベースで医薬品開発から医薬品製造までの包括的なサービスを提供する会社です。これにより、主要なバイオ製薬会社は、ビジネスのこれらの側面をアウトソーシングすることができ、スケーラビリティを支援したり、大手企業が創薬やドラッグマーケティングに集中したりできるようになります。バイオ医薬品業界のアウトソーシング量の増加、 研究開発への投資の増加、受託製造組織(CMO)のサービス提供の拡大は、バイオ医薬品受託製造市場の主要な推進要因です。

当レポートは世界のバイオ医薬品受託製造市場について調査しており、市場機会や動向、成長および抑制要因、セグメント別や地域別の市場分析、競合情勢、主要企業のプロファイル等の情報を提供しています。

目次

第1章 イントロダクション

  • 調査の前提条件
  • 調査範囲

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場力学

  • 市場概要
  • 市場成長要因
    • バイオ医薬品産業でのアウトソーシング量の増加
    • 研究開発への投資の増加
    • CMOのサービス提供の拡大
  • 市場抑制要因
    • 厳しい規制要件
    • 物流コストの増加
  • ポーターのファイブフォース分析
    • 新規参入の脅威
    • バイヤー/消費者の交渉力
    • サプライヤーの交渉力
    • 代替製品の脅威
    • 競争の激化

第5章 市場区分

  • 製品タイプ別
    • ペプチド/タンパク質
    • 抗体
    • ワクチン
    • バイオシミラー
    • その他
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋地域
    • 中東・アフリカ地域
    • 南米

第6章 競合情勢

  • 企業プロファイル
    • Boehringer Ingelheim GmbH
    • Lonza Group
    • Inno Biologics Sdn Bhd
    • Rentschler Biotechnologie GmbH
    • JRS Pharma (Celonic)
    • Samsung BioLogics
    • WuXi Biologics
    • AGC Biologics
    • ProBioGen AG
    • FUJIFILM Diosynth Biotechnologies USA, Inc

第7章 市場機会および将来動向

目次
Product Code: 67981

The Biopharmaceuticals Contract Manufacturing Market is expected to register a CAGR of 7.5% during the forecast period. A contract manufacturing organization (CMO) is a company that serves other companies in the biopharmaceutical industry on a contract basis to provide comprehensive services from drug development through drug manufacturing. This allows major biopharmaceutical companies to outsource those aspects of the business, which can help with scalability or can allow the major company to focus on drug discovery and drug marketing. Biotechnology industries continue to outsource to contract manufacturing organizations (CMOs) to meet their fill-and-finish needs and reduce risk. Some small biotechnology companies outsource their fill-and-finish manufacturing needs because they do not have the in-house capacity and helps obviate the need for capital expenditures and reduces business risk. Moreover, the outsourcing strategy for these companies is highly complex and varies depending on the product life cycle, product phase, volume, and profitability. Some other influencing factor in an outsourcing decision is a company's view on fill-and-finish's importance to their drug product portfolio. The current market structure presents biopharmaceutical companies with a shortage of contract manufacturing organization (CMO) capacity to produce biopharmaceuticals, especially in cell culture technology and new modalities and even as demand for outsourcing increases.

Biopharmaceuticals large molecules differ from pharmaceutical small molecules in their size, behavior, their manufacture and the way large molecules work in the human body. manufacturing such large molecules is significantly more complex than producing traditional pharmaceuticals. In fact, biopharma is a highly technical industry, with complex processes involved that relatively few players have entirely mastered. Biopharmaceutical companies growing steadily for several years, and the presence of large pipeline molecules in clinical trials promise continued growth.

Currently, more than 235 companies offer contract manufacturing services for biopharmaceuticals, to handle multiple types of biologics. Majority of the contract manufacturing organizations (CMO) offer services for proteins/peptides, antibodies and vaccines. In addition, mammalian cell-based manufacturing is more popular than microbial expression systems this trend is expected to persist in the coming years as well.

Increasing outsourcing volume by biopharmaceutical industries, increasing investments in research and development and expansion in the service offering of contract manufacturing organizations (CMOs)are the key driving factors in the biopharmaceuticals contract manufacturing market.

Key Market Trends

Antibodies segment is Expected to Witness Robust Growth

Monoclonal antibody therapy is a type of immunotherapy that uses antibodies to bind to certain cells or proteins and will stimulate the patient's immune system to attack those cells. These therapeutic agents are used for the treatment of different cancers. Monoclonal antibodies are the most important class of biologics. Monoclonal antibodies approval has accounted for almost 20% of all drugs authorized by the FDA in the year 2018. This number had exceeded compared to approvals in the previous years, thus leading to the approval of 27 antibody-based drugs out of a total of 127 new drugs over the past three years.

Antibodies segment holds a significant market share in the biopharmaceuticals contract manufacturing market and is anticipated to show a similar trend over the forecast period. According to Food and Drug Administration (FDA), it has approved 17 biologics in the year 2018, of which 12 are monoclonal antibodies (mAb), three pegylated enzymes, one protein, and one fusion protein.

Technological advancements in monoclonal antibody therapy and increasing research and development activities are the key driving factors in the antibodies segment.

North America is Expected to Hold a Significant Share in the Market and Expected to do Same in the Forecast Period

North America is expected to hold a major market share in the global biopharmaceuticals contract manufacturing market due to presence of number of biopharmaceutical companies with large production capacities leading to high consumption of biologics in this region. Furthermore, growing emphasis on superior biopharmaceutical products, biosimilars led to the increase in the demand for biologicals, biopharmaceutical based research and development activities accounted for a major percentage of the total research and development carried out in various sectors is also fueling the growth of the overall regional market to a large extent.

Competitive Landscape

The Biopharmaceuticals Contract Manufacturing Market is consolidated and consists of few major players. In terms of market share, few of the major players are currently dominating the market. Some of the companies which are currently dominating the market are Boehringer Ingelheim GmbH, Lonza, Inno Biologics Sdn Bhd, Rentschler Biotechnologie GmbH, JRS Pharma (Celonic), Samsung BioLogics, WuXi Biologics, AGC Biologics, ProBioGen AG and FUJIFILM Diosynth Biotechnologies U.S.A., Inc.

Reasons to Purchase this report:

  • The market estimate (ME) sheet in Excel format
  • Report customization as per the client's requirements
  • 3 months of analyst support

Table of Contents

1 INTRODUCTION

  • 1.1 Study Assumptions
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Increasing Outsourcing Volume by Bio-pharmaceutical Industries
    • 4.2.2 Increasing Investments in Research and Development
    • 4.2.3 Expansion in the Service Offering of CMOs
  • 4.3 Market Restraints
    • 4.3.1 Stringent Regulatory Requirements
    • 4.3.2 Increasing Logistics Costs
  • 4.4 Porter's Five Force Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION

  • 5.1 By Product Type
    • 5.1.1 Peptides/Proteins
    • 5.1.2 Antibodies
    • 5.1.3 Vaccines
    • 5.1.4 Biosimilars
    • 5.1.5 Others
  • 5.2 Geography
    • 5.2.1 North America
      • 5.2.1.1 United States
      • 5.2.1.2 Canada
      • 5.2.1.3 Mexico
    • 5.2.2 Europe
      • 5.2.2.1 Germany
      • 5.2.2.2 United Kingdom
      • 5.2.2.3 France
      • 5.2.2.4 Italy
      • 5.2.2.5 Spain
      • 5.2.2.6 Rest of Europe
    • 5.2.3 Asia-Pacific
      • 5.2.3.1 China
      • 5.2.3.2 Japan
      • 5.2.3.3 India
      • 5.2.3.4 Australia
      • 5.2.3.5 South Korea
      • 5.2.3.6 Rest of Asia-Pacific
    • 5.2.4 Middle-East and Africa
      • 5.2.4.1 GCC
      • 5.2.4.2 South Africa
      • 5.2.4.3 Rest of Middle-East and Africa
    • 5.2.5 South America
      • 5.2.5.1 Brazil
      • 5.2.5.2 Argentina
      • 5.2.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 Boehringer Ingelheim GmbH
    • 6.1.2 Lonza Group
    • 6.1.3 Inno Biologics Sdn Bhd
    • 6.1.4 Rentschler Biotechnologie GmbH
    • 6.1.5 JRS Pharma (Celonic)
    • 6.1.6 Samsung BioLogics
    • 6.1.7 WuXi Biologics
    • 6.1.8 AGC Biologics
    • 6.1.9 ProBioGen AG
    • 6.1.10 FUJIFILM Diosynth Biotechnologies U.S.A., Inc

7 MARKET OPPORTUNITIES AND FUTURE TRENDS

株式会社グローバルインフォメーション
© Copyright 1996-2020, Global Information, Inc. All rights reserved.